Introduction {#s001}
============

M[ethodologically sound analyses]{.smallcaps} estimate the prevalence of autism spectrum disorder (ASD) (American Psychiatric Association [@B2]) at 60--70 children per 10,000 (i.e., at 0.6--0.7%) (Fombonne [@B16]; Elsabbagh et al. [@B12],); in addition, the prevalence appears to have increased over the past decades (Rosenberg et al. [@B31]). In children with ASD, risperidone and aripiprazole can be used to treat the associated symptoms of irritability, aggression, self-injury, temper tantrums, and mood swings (McCracken et al. [@B25]; Curran [@B10]). However, no medications are currently approved for treating the core domains of ASD (impaired social communication and interaction, and stereotyped behaviors and restricted interests), which represents a challenging unmet medical need (Mohiuddin and Ghaziuddin [@B26]; Rossi et al. [@B32]; Yudell, et al. [@B37]).

Glutamate is the principal excitatory neurotransmitter in the brain, and several lines of evidence implicate aberrant glutamatergic neurotransmission in the pathophysiology of ASD (Choudhury et al. [@B7]). For example, increased glutamate levels in plasma samples have been observed in children with ASD (Moreno-Fuenmayor et al. [@B27]). Also, levels of glutamate decarboxylase, the enzyme responsible for conversion of glutamate to γ-aminobutyric acid (GABA), were found to be lower in the postmortem brain tissue of patients with ASD (Fatemi et al. [@B14]). Levels of the glutamatergic *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor, which is instrumental for learning and formation of memory, have been shown to be high in the postmortem brain tissue of individuals diagnosed with ASD (Wenk et al. [@B36]; Blue et al. [@B5]; Purcell et al. [@B30]). Further, cellular abnormalities such as reduced neuronal cell size, increased cell packing density, and decreased complexity and arborization of pyramidal cells in the limbic system and reduced number of Purkinje cells in the cerebellum are consistently observed in the postmortem brain tissue of individuals diagnosed with ASD (Bauman and Kemper [@B3]); these abnormalities are located in brain regions where NMDA receptors are abundant (e.g., the hippocampus and cerebellum) (Collingridge and Watkins [@B8]).

Memantine is a moderate-affinity, uncompetitive NMDA receptor antagonist with strong voltage dependency and rapid blocking/unblocking kinetics (Danysz and Parsons [@B11]) that is approved for the treatment of moderate to severe Alzheimer\'s disease (AD) (Namenda XR [@B28]). In randomized, placebo-controlled trials in patients with AD, memantine was shown to improve functional communication (Tocco et al. [@B34]). In addition, data from pediatric studies have suggested good tolerability and potential clinical benefits of memantine in children with ASD. For example, 8 weeks of memantine treatment (10 or 20 mg once daily) in 16 children (6--12 years of age) with attention-deficit/hyperactivity disorder (ADHD) required no dose reduction, and there were no adverse events (AEs) leading to discontinuation or potentially clinically significant (PCS) changes in other measures of safety (hematology, vital signs, electrocardiogram \[ECG\]) (Findling et al. [@B15]). Further, prospective and retrospective open-label studies suggested that memantine can improve social interaction and communication in children with ASD (Owley, et al. [@B29]; Chez et al. [@B6]; Erickson et al. [@B13]) and a 10 week randomized trial in children with autism demonstrated significant benefits of risperidone plus memantine over risperidone plus a placebo on the Irritability, Stereotypic Behavior, and Hyperactivity/Noncompliance subscales of the Aberrant Behavior Checklist (ABC) (Ghaleiha et al. [@B17]).

We report here the results of a randomized, placebo-controlled, proof-of-concept, phase I--II study and its open-label extension (OLEX), which investigated the efficacy, safety, and tolerability of memantine extended-release (ER) in children with autism. The efficacy hypothesis was that memantine ER treatment would improve social interaction and communication in children with autism.

Methods {#s002}
=======

Study design {#s003}
------------

The two studies described here were conducted at multiple centers in the United States between April, 2009 and February, 2013 in children diagnosed with autistic disorder, defined at the time of the study using *Diagnostic and Statistical Manual of Mental Disorders,* 4th ed., Text Revision (DSM-IV-TR) criteria (American Psychiatric Association [@B2]).

The first study, MEM-MD-57A Part 2 (NCT00872898), was a 12 week, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose (first 8 weeks) and target dose (3--15 mg/day) trial conducted to determine safety, tolerability, and efficacy of memantine ER in children with autism. The daily dosage of memantine ER to be administered was based on weight groups: 1) Group A, ≥ 60 kg, maximum dose of 15 mg/day; 2) Group B, 40--59 kg, maximum of 9 mg/day; 3) Group C, 20--39 kg, maximum of 6 mg/day; and 4) Group D, \<20 kg, maximum of 3 mg/day. These maximum dose limits were selected to ensure that the plasma exposure to memantine (the area under the curve \[AUC\] of plasma concentration versus time) remained below the predefined safety limit, which represented a 10-fold lower exposure than the no-observed-adverse-effect-level (NOAEL) established in juvenile rat studies. Two preceding pharmacokinetic (PK) dose-finding studies were completed in children with ASD and other pathologies (MEM-PK-21 and MEM-MD-57A Part 1; results not reported here) to establish the PK parameters, safety, and tolerability of these doses for the weight groups. Although we reference these PK protocols, no data from the PK subjects are presented in this report, with the exception of tolerability measures. All study medication during MEM-MD-57A Part 2 was administered in a single daily dose (3 mg or 6 mg memantine ER capsules; up to three capsules) taken orally, preferably at the same time each day of the study. Dosages of memantine ER were uptitrated from 3 mg/day to the target doses of 3--15 mg/day.

MEM-MD-57A Part 2 was a phase II trial in which the participants were randomized 1:1 to receive placebo or memantine ER in accordance with the United States Food and Drug Administration (FDA) Guidance for Industry (United States Food and Drug Administration [@B35]). The randomization codes were generated and securely retained by the Statistical Programming and Drug Safety Surveillance Department at Forest Research Institute, Inc. Following 2 weeks of single-blind placebo treatment, memantine ER treatment was initiated at a dosage of 3 mg per day and uptitrated for ≤8 weeks (depending upon the weight group), which allowed for ≥4 weeks of maintenance treatment at a target dose (14 weeks total, including 2 weeks of single-blind placebo).

The OLEX study (MEM-MD-67; NCT01999894) was a 48 week, multicenter trial that evaluated the long-term safety and tolerability of memantine ER in the same children. All participants who completed the lead-in study MEM-MD-57A Part 2 were eligible to enroll. The study consisted of a 6 week, double-blind, dose-titration period followed by a 42 week open-label maintenance period. The double-blind dose titration permitted the participants who were randomized to receive placebo in the lead-in study to be uptitrated to their weight-based target dosage and permitted those who were randomized to receive memantine ER to maintain their previous dosage without compromising the lead-in study blind. (Participants retained their randomization codes from the lead-in study; the protocol required maintaining the double blind for the first 6 weeks of the extension trial, during which memantine ER dosages were either uptitrated \[in children previously assigned to placebo\] or maintained \[in children previously treated with memantine\]). The study design and dosing for MEM-MD-57A Part 2 and the OLEX are shown in [Figure 1](#f1){ref-type="fig"}.

![Combined study design and dosing for MEM-MD-57A Part 2 and the open-label extension (OLEX). Dose titration in MEM-MD-67 only for participants who were previously randomized to placebo. Participants taking memantine ER during MEM-MD-57A continued with same dose.](fig-1){#f1}

Participants {#s004}
------------

Participants in MEM-MD-57A Part 2 were children 6--12 years of age who met the DSM-IV-TR (American Psychiatric Association [@B2]) criteria for autistic disorder based on a clinical evaluation and information derived from modules 2 and 3 of the Autism Diagnostic Observation Schedule (ADOS) (Gotham et al. [@B18]) and the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al. [@B23]). Participants were also required to have: 1) Verbal fluency of at least three-word phrases in English, 2) ABC---Community (ABC--C) (Aman et al. [@B1]) irritability subscale score \<17 (in order to minimize manifestations of irritability during the study), 3) Social Responsiveness Scale (SRS) (Constantino and Gruber [@B9]) raw total score \>44 (girls) or \>53 (boys), and 4) intelligence quotient (IQ) ≥50 on the Kaufman Brief Intelligence Test, Version 2, which denotes an IQ in the range of mild intellectual disability to normal ability. Inclusion criteria for the OLEX study were the completion of MEM-MD-57A Part 2, normal physical examination and laboratory test results at the first study visit of the OLEX study or the final visit of MEM-MD-57A Part 2 (if within 14 days), and negative urine pregnancy test results for girls ≥9 years of age. Participants who completed the PK studies MEM-MD-57A Part 1 or MEM-PK-21, which included children and adolescents 5--16 years of age diagnosed with autistic disorder (DSM-IV-TR), who did not fulfill the inclusion criteria for Part 2, were also eligible for enrollment in the OLEX at the investigator\'s discretion, to provide compassionate care for those individuals. Data for these subjects were not included in this report.

Exclusion criteria for MEM-MD-57A Part 2 were premature birth (before 35 weeks) or low birth weight (\<2.3 kg), history of neurological disease, including chromosomal and active seizure disorders, use of prohibited medications (antianginal, antiarrhythmic, anticoagulant, antihypertensive, antineoplastic, diuretic, hypoglycemic or hypolipidemic agents; insulin; muscle relaxants; systemic antifungal agents or steroids; hormone suppressants; or psychotropic drugs. ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}; Supplementary Data are available online at [www.liebertpub.com/cap](www.liebertpub.com/cap)) and a primary psychiatric diagnosis other than autism. These exclusion criteria were also used for the OLEX trial. Post-menarcheal girls had to agree to use an investigator-approved method of contraception. Written informed consents were collected from participants, when possible, and consents were obtained from the caregiver or from a parent, guardian, or legally authorized representative before the initiation of any study-specific procedures. The studies were reviewed and approved by the institutional review board at each site.

Efficacy variables {#s005}
------------------

In MEM-MD-57A Part 2, the primary efficacy variable at end-point was the change from baseline to Week 12 in the SRS total raw score (Constantino and Gruber [@B9]). The SRS is a 65 item instrument consisting of five subscales designed to assess social awareness, information processing, capacity for reciprocal response, anxiety/avoidance, and autistic preoccupations and traits. Each item is rated on a four point scale, with a higher score indicating greater impairment. The caregiver completed the SRS based on the patient\'s behavior over the previous 6 weeks at the beginning of the study (Baseline), Week 6, and Week 12 or at early termination of the study.

The secondary efficacy parameters were Core Autism Treatment Scale-Improvement (CATS-I) (a proprietary instrument, not yet validated) total score and subscales (social interaction and communication) at Week 12, and the change from baseline to Week 12 in 10 subscales of the Children\'s Communication Checklist-2 (CCC-2) (Bishop [@B4]). The CATS is a 14 item scale developed by the memantine autism research program team, which assesses social interaction (items 1--9) and communication (items 10--14). It consists of a severity component (CATS-S) administered at baseline and an improvement component (CATS-I) administered at every subsequent visit (Weeks 2, 4, 6, 8, 10, and 12). The subscales are scored from 1 to 7, with higher scores indicating greater impairment. The CCC-2 is a validated, norm-referenced, informant-rated scale that assesses difficulties that affect communication (items 1--50) and strengths that may be demonstrated during communication (items 51--70). The 10 subscales are rated from 0 to 3 (higher scores indicate greater impairment) and assess speech, syntax, semantics, coherence, initiation, scripted language, context, nonverbal communication, social relations, and interests. The CCC-2 was administered at baseline and at Weeks 6 and 12.

Additional efficacy parameters included the Core and Associated Autism Symptom Treatment Scale (CAASTS) (a proprietary instrument, not yet validated, containing 23 items that test for stereotyped behaviors and restricted interests, associated maladaptive behaviors, and daily function), with a severity component (CAASTS-S) administered at baseline, and an improvement component (CAASTS-I) administered at every subsequent visit (Weeks 2, 4, 6, 8, 10, and 12). The Clinical Global Impressions-Severity subscale (CGI-S) (Guy [@B19]) was administered at baseline and last visit, and the CGI Improvement subscale was administered at Weeks 2, 4, 6, 8, 10, and 12. The CGI scale was completed separately to evaluate the domains of social interaction, communication, integrated social interaction and communication, stereotyped behavior, restricted interests, associated maladaptive behaviors, and daily function. The ABC-C (Aman et al. [@B1]), was administered at baseline and at Weeks 6 and 12; and the Autism Health Economics and Outcomes Questionnaire (AHEOQ), developed by the sponsor, was also administered at baseline and at Weeks 6 and 12. The ABC-C is a 58 item, informant-rated behavior rating scale with subscales assessing irritability (15 items; administered only at screening, to determine inclusion), stereotypy (7 items), hyperactivity (16 items), and inappropriate speech (4 items). The AHEOQ is designed to measure the direct and indirect financial burden of autism and to assess caregiver and family burden using a caregiver-completed questionnaire and two validated subscales: The Parenting Stress Index (Loyd and Abidin [@B24]) and the Health Utilities Index (Horsman, et al. [@B20]).

In the OLEX study, no efficacy parameters were considered primary. Additional efficacy variables were considered exploratory and included the SRS, CATS-I, CAASTS-I, CCC-2, CGI-S, CGI-I, and ABC-C. Efficacy assessments in the OLEX took place at the first visit and weeks 12, 24, 36, 48, and 60, or early termination date.

Safety and tolerability {#s006}
-----------------------

The safety population comprised all randomized participants who took at least one dose of the double-blind investigational product in MEM-MD-57A Part 2. The Part 2 autism safety population comprised all participants in the safety population who had autistic disorder and also met all of the Part 2 inclusion/exclusion criteria (i.e., participants from the PK studies who did not meet age or diagnostic criteria were not included in the autism safety population). Blood samples were drawn in all participants for PK analyses at Weeks 2, 4, and 12 or upon early termination, in order to confirm that actual AUC drug exposure was conforming to the predefined safety limit. In the OLEX study, blood samples for PK analyses were collected at Weeks 2, 24, and 48 or early termination. In both studies, vital signs were monitored at each clinic visit. A complete physical examination was performed at screening and the last visit. A standard 12 lead ECG and clinical laboratory tests (hematology, chemistry, and urinalysis) were performed at screening, baseline (excluding urine test), and the last visit or early termination; a urine drug screen was performed at Visit 1 only if deemed necessary by the investigator.

Statistical analysis {#s007}
--------------------

All efficacy analyses for MEM-MD-57A Part 2 were based on the autism intention-to-treat (ITT) population, which was defined as all randomized participants who satisfied Part 2 inclusion and exclusion criteria, took at least one dose of the double-blind medication, and had at least one postbaseline SRS measurement. Baseline was defined as the last nonmissing efficacy assessment on or before the date of the first dose of the investigational product. Unless stated otherwise, all statistical tests were two sided (α = 0.05). The analysis of the primary and secondary efficacy parameters in MEM-MD-57A Part 2 was performed using a mixed-effects model with repeated measures (MMRM) that included treatment group, study center, visit, and treatment-by-visit interaction as fixed effects and the baseline score and baseline-score-by-visit interaction as covariates based on the observed cases (OC). An unstructured covariance matrix was used to model covariance of within-patient scores. Two sensitivity analyses were also performed for the primary efficacy variable: One based on the last observation carried forward (LOCF) approach for imputing missing values and using an analysis of covariance (ANCOVA) model with treatment group and study center as the factors and baseline value as the covariate, and one using a pattern-mixture model based on non-future-dependent missing value restrictions (Kenward et al. [@B21]), performed to assess the robustness of the primary MMRM results to possible violation of the missing-at-random assumption. The secondary and additional efficacy variables were analyzed using an MMRM or an ANCOVA model, as indicated in the text, except for the CGI-I subscales, which were analyzed using a Cochran--Mantel--Haenszel test with modified ridit scores, controlling for study center. In the OLEX (MEM-MD-67), efficacy parameters were analyzed using descriptive statistics based on the OC. SAS version 9.1.3 or newer (SAS Institute, Cary, NC) was used for all analyses. Safety parameters were analyzed using descriptive statistics.

Results {#s008}
=======

Participants {#s009}
------------

A total of 222 children were screened for the MEM-MD-57A Part 2 trial including 1 child who completed the MEM-MD-57A Part 1 trial, and 6 children who completed MEM-PK-21 ([Fig. 2](#f2){ref-type="fig"}). Of the 121 children who enrolled in Part 2, 104 completed the trial (placebo: 82.0%; memantine: 90.0%) and 102 enrolled in the OLEX ([Fig. 2](#f2){ref-type="fig"}). None of the seven children who entered MEM-MD-57A Part 2 from Part 1 or from MEM-PK-21 were included in the autism ITT population (five because of absence of verbal fluency; two because they exceeded the prespecified age limit). The most common protocol deviations during MEM-MD-57A Part 2 were related to the use of prohibited concomitant medications (placebo: 27.9%; memantine: 35.0%); the most common categories of prohibited medications were antihistamines for systemic use (six in each group) and cough and cold preparations (placebo, *n* = 2; memantine, *n* = 9). In Part 2, all six discontinuations (10.0%) in the memantine arm occurred within the first 8 weeks of double-blind treatment, corresponding to the titration phase; in the placebo arm, seven participants (11.5%) discontinued treatment during Weeks 1--8 and four participants (6.6%) discontinued after Week 8. The completion rate in the OLEX was 64.7% ([Fig. 2](#f2){ref-type="fig"}), and the most common protocol deviation was the use of prohibited concomitant medication (20.6%); the most common prohibited medications were cough and cold preparations (*n* = 7) and methylphenidate HCl (*n* = 4).

![Combined study flow for trials MEM-MD-57A (Part 1 and Part 2) and MEM-MD-67 (open-label extention \[OLEX\]). ITT indicates intention-to-treat. MEM-MD-57A Part 2 autism safety population: Subjects (*n* = 114) had only autistic disorder according to the *Diagnostic and Statstical Manual of Mental Disorders,* 4th ed., Text Revision (DSM-IV-TR). The larger safety population (*n* = 121) included children with pervasive developmental disorder not otherwise specified (PDD-NOS) and/or Asperger\'s disorder.](fig-2){#f2}

The demographic and clinical characteristics for both trials are summarized in [Table 1](#T1){ref-type="table"}. In MEM-MD-57A Part 2, the groups were well matched at baseline. The majority of participants were white males. Almost all participants (90.9%) were in the two middle weight classes (groups B and C), weighing between 20 and 59 kg. For MEM-MD-57A Part 2, the mean final daily dosages were 14.4 mg/day, 8.3 mg/day, 5.9 mg/day, and 3.0 mg/day for Groups A, B, C, and D, respectively, and for the OLEX, the mean final daily dose was 7.9 mg/day.

###### 

[Demographic and Clinical Characteristics at Baseline (Safety Population)]{.smallcaps}^[a](#tf1){ref-type="table-fn"}^

                                                                                         *MEM-MD-57A Part 2 (Double-blind)*   *MEM-MD-67 (Open-label extension)*                  
  -------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------ -------------- --------------
  Age, years^[b](#tf2){ref-type="table-fn"}^                                             8.9 ± 2.2                            9.0 ± 2.2                            9.1 ± 2.3      9.1 ± 2.2
  Boys, *n* (%)                                                                          49 (80.3)                            52 (86.7)                            41 (82.0)      46 (88.5)
  Race, *n* (%)                                                                                                                                                                   
   White                                                                                 49 (80.3)                            50 (83.3)                            42 (84.0)      44 (84.6)
   Asian                                                                                 6 (9.8)                              5 (8.3)                              4 (8.0)        5 (9.6)
   Black                                                                                 3 (4.9)                              1 (1.7)                              1 (2.0)        1 (1.9)
   Other                                                                                 3 (4.9)                              4 (6.7)                              3 (6.0)        2 (3.8)
  Weight group distribution, *n* (%)                                                                                                                                              
   Group A (≥60 kg)                                                                      4 (6.6)                              5 (8.3)                              n/a            n/a
   Group B (40-59 kg)                                                                    14 (23.0)                            17 (28.3)                            n/a            n/a
   Group C (20-39 kg)                                                                    42 (68.9)                            37 (61.7)                            n/a            n/a
   Group D (\<20 kg)                                                                     1 (1.6)                              1 (1.7)                              n/a            n/a
  Education Status, *n* (%)                                                                                                                                                       
   Public School                                                                         48 (78.7)                            48 (80.0)                            n/a            n/a
   Private School                                                                        5 (8.2)                              5 (8.3)                              n/a            n/a
   Home School                                                                           1 (1.6)                              2 (3.3)                              n/a            n/a
   Other                                                                                 6 (9.8%)                             5 (8.3)                              n/a            n/a
  K-BIT2 score^[b](#tf2){ref-type="table-fn"}^                                                                                                                                    
   IQ composite                                                                          75.7 ± 19.4                          77.9 ± 23.1                          75.9 ± 19.8    78.2 ± 23.8
   Verbal score                                                                          36.4 ± 19.4                          37.0 ± 16.2                          35.6 ± 18.2    37.4 ± 16.3
   Nonverbal score                                                                       32.1 ± 26.1                          26.3 ± 18.1                          31.6 ± 25.8    25.9 ± 17.8
  ADOS Score^[b](#tf2){ref-type="table-fn"}^                                                                                                                                      
   Communication                                                                         6.3 ± 2.1                            6.3 ± 2.2                            n/a            n/a
   Social interaction                                                                    11.0 ± 2.8                           10.3 ± 2.5                           n/a            n/a
   Total                                                                                 17.3 ± 4.5                           16.7 ± 4.2                           n/a            n/a
   SRS, Total Raw Score^[b](#tf2){ref-type="table-fn"},[c](#tf3){ref-type="table-fn"}^   100.2 ± 21.4                         101.3 ± 25.2                         100.5 ± 19.7   102.2 ± 25.5

The safety population in trials MEM-MD-57A Part 2 and MEM-MD-67 included seven children with autism spectrum disorder who did not have autism.

Mean ± standard deviation.

MEM-MD-57A Part 2: Autism ITT population (placebo, *n* = 53, memantine, *n* = 54); MEM-MD-67: Autism safety population (placebo/memantine, *n* = 46; memantine/memantine, *n* = 47).

ADOS, Autism Diagnostic Observation Schedule; IQ, intelligence quotient; K-BIT2, Kaufman Brief Intelligence Test, Version 2; Mem, extended-release memantine; SRS, Social Responsiveness Scale.

Efficacy {#s010}
--------

Analysis of the change from baseline in SRS total raw score at Week 12 in MEM-MD-57A Part 2 showed no statistically significant difference between the treatment groups (least squares mean difference \[95% confidence interval\]: −0.1 \[−7.2, 6.6\], *p* = 0.978) ([Fig. 3](#f3){ref-type="fig"}). Sensitivity analyses yielded similar results. (Analyses of SRS subscales also showed no significant between-group differences \[data not shown\].) However, at Week 12, both groups attained a clinically significant improvement from baseline of ∼10 points (see [Discussion](#s012){ref-type="sec"}). In the OLEX, the participants maintained an overall nominal improvement from Week 12 to the end of study of ∼6 points, regardless of the previous treatment group assignment in MEM-MD-57A Part 2 ([Fig. 3](#f3){ref-type="fig"}). From MEM-MD-57A Part 2 baseline to the end of the OLEX, there was an overall mean improvement of ∼15.6 points in SRS total raw score for all study participants ([Fig. 3](#f3){ref-type="fig"}).

![Changes from baseline in Social Responsiveness Scale (SRS) total raw score (autism intent-to-treat \[ITT\] population). In the lead-in trial (MEM-MD-57A Part 2), mixed-effects model with repeated measures (MMRM) approach based on observed cases was performed, and in the open-label extention (OLEX) study (MEM-MD-67) only descriptive statistics were analyzed; therefore, the presented changes from baseline are least squares means from the MMRM model for MEM-MD-57A Part 2, and ordinary means for MEM-MD-67. Mem, extended-release memantine; Pbo, placebo; SEM, standard error of the mean.](fig-3){#f3}

There were no statistically significant between-group differences in CATS-I total or subscale scores at Week 12, but both groups demonstrated overall improvement versus baseline that was maintained or increased during the OLEX ([Supplementary Fig. S1](#SD2){ref-type="supplementary-material"}). In addition, there were no significant between-group differences on nine of the 10 CCC-2 subscales at Week 12; however, there was a significant difference favoring placebo in the context subscale (*p* = 0.02) ([Fig. 4](#f4){ref-type="fig"}).

![Score changes from baseline at Week 12 (MEM-MD-57A Part 2: Pbo, Mem) and Week 60 or end of study (MEM-MD-67: Pbo/Mem, Mem/Mem) in Children\'s Communication Checklist, 2nd ed. (CCC-2) Subscales (autism intent-to-treat \[ITT\] population). In MEM-MD-57A Part 2 the mixed-effect model repeated measures (MMRM) approach based on observed cases was performed, and in MEM-MD-67 only descriptive statistics were analyzed. Therefore, the score changes from baseline are least squares means from MMRM model for MEM-MD-57A Part 2 and ordinary means for MEM-MD-67. \**p* = 0.02. Mem, extended-release memantine; Pbo, placebo; SEM, standard error of the mean.](fig-4){#f4}

Finally, there were no statistically significant differences between the treatment groups on any of the additional efficacy measures.

Safety and tolerability {#s011}
-----------------------

In the MEM-MD-57A Part 2 safety population, only one serious AE was reported; that of mood disorder (judged to be unrelated to the study medication) in a memantine ER-treated participant who was one of the few participants with ASD who did not meet the criteria for the diagnosis of autistic disorder. A total of seven participants discontinued treatment because of an AE (placebo, *n* = 4 \[6.6%\]; memantine, *n* = 3 \[5.0%\]) ([Fig. 2](#f2){ref-type="fig"}). All treatment-emergent AEs (TEAEs) were mild or moderate in severity, except for three in the memantine group (irritability, affective disorder, choking); the occurrence of affective disorder in one participant was also considered a serious AE (SAE). TEAEs were experienced by 47 (77.0%) placebo-treated and 51 (85.0%) memantine ER-treated participants ([Table 2](#T2){ref-type="table"}); of those, 33 (54.1%) and 36 (60.0%), respectively, experienced a TEAE deemed related to study medication. The most common TEAEs that occurred in the memantine group at a higher incidence than in the placebo group were irritability (6.7% vs. 3.3%) and aggression (6.7% vs. 4.9%).

###### 

[Trials MEM-MD-57A Part 2 and MEM-MD-67: Common TEAEs (Safety Population), *n* (%)]{.smallcaps}

                                                                         *MEM-MD-57A Part 2 (12 Weeks)*   *MEM-MD-67 (48 Weeks)*   
  ---------------------------------------------------------------------- -------------------------------- ------------------------ -----------
  Any TEAE                                                               47 (77.0)                        51 (85.0)                85 (83.3)
  TEAEs with incidence ≥3% in either group in trial MEM-MD-57A, Part 2                                                             
   Upper respiratory tract infection                                     7 (11.5)                         6 (10.0)                 15 (14.7)
   Cough                                                                 3 (4.9)                          6 (10.0)                 10 (9.8)
   Irritability                                                          3 (4.9)                          5 (8.3)                  7 (6.9)
   Aggression                                                            3 (4.9)                          5 (8.3)                  8 (7.8)
   Vomiting                                                              6 (9.8)                          4 (6.7)                  8 (7.8)
   Insomnia                                                              3 (4.9)                          4 (6.7)                  8 (7.8)
   Influenza                                                             2 (3.3)                          4 (6.7)                  5 (4.9)
   Agitation                                                             1 (1.6)                          4 (6.7)                  6 (5.9)
   Headache                                                              3 (4.9)                          3 (5.0)                  7 (6.9)
   Rhinorrhea                                                            0                                3 (5.0)                  3 (2.9)
   Nasopharyngitis                                                       6 (9.8)                          2 (3.3)                  7 (6.9)
   Pyrexia                                                               4 (6.6)                          2 (3.3)                  6 (5.9)
   Diarrhea                                                              3 (4.9)                          2 (3.3)                  5 (4.9)
   Ear infection                                                         1 (1.6)                          2 (3.3)                  5 (4.9)
   Laceration                                                            1 (1.6)                          2 (3.3)                  0
   Rhinitis, allergic                                                    1 (1.6)                          2 (3.3)                  5 (4.9)
   Stereotypy                                                            1 (1.6)                          2 (3.3)                  5 (4.9)
   Affective disorder                                                    0                                2 (3.3)                  1 (1.0)
   Enuresis                                                              0                                2 (3.3)                  2 (2.0)
   Frequent bowel movements                                              0                                2 (3.3)                  1 (1.0)
   Nasal congestion                                                      5 (8.2)                          1 (1.7)                  8 (7.8)
   Psychomotor hyperactivity                                             4 (6.6)                          1 (1.7)                  6 (5.9)
   Abdominal pain, upper                                                 3 (4.9)                          1 (1.7)                  4 (3.9)
   Oropharyngeal pain                                                    3 (4.9)                          1 (1.7)                  2 (2.0)
   Abnormal behavior                                                     2 (3.3)                          1 (1.7)                  1 (1.0)
   Nausea                                                                2 (3.3)                          1 (1.7)                  2 (2.0)
   Anxiety                                                               4 (6.6)                          0                        4 (3.9)
   Seasonal allergy                                                      3 (4.9)                          0                        9 (8.8)
   Abdominal pain                                                        2 (3.3)                          0                        1 (1.0)
   Nosebleed (epistaxis)                                                 2 (3.3)                          0                        3 (2.9)
  Additional TEAEs, with occurrence ≥3% in trial MEM-MD-67                                                                         
   Weight increased^[a](#tf5){ref-type="table-fn"}^                      0                                0                        9 (8.8)
   Constipation                                                          1 (1.6)                          1 (1.7)                  7 (6.9)
   Initial insomnia                                                      1 (1.6)                          1 (1.7)                  4 (3.9)
   Pharyngitis, streptococcal                                            0                                1 (1.7)                  4 (3.9)

Post-hoc analyses of age-adjusted changes in body weight indicates that most instances of weight gain in the trial MEM-MD-67 were associated with children\'s growth (data not shown).

TEAE categories are ordered by decreasing incidence in the memantine group.

Mem, extended-release memantine; TEAE, treatment-emergent adverse event.

In the OLEX, one patient experienced an SAE (lobar pneumonia, deemed unrelated to treatment) and nine participants (8.8%) discontinued because of TEAEs. Four participants (3.9%) experienced five TEAEs that were considered severe (acne, acrodermatitis, pyrexia, and two cases of bronchitis) and also unrelated to the study medication. One TEAE (negativism), which was considered related to the treatment, resulted in the patient discontinuing treatment after 201 days. There were no PCS changes in ECG parameters. There were a few instances of PCS changes in laboratory parameters but none were associated with SAEs or AEs. The mean changes from baseline in laboratory values were generally small and not clinically meaningful ([Supplementary Table S1](#SD3){ref-type="supplementary-material"}).

The mean weight changes from baseline to Week 12 in MEM-MD-57A, Part 2 were 0.9 ± 2.0 kg (placebo) and 1.2 ± 1.9 kg (memantine ER). Over the duration of MEM-MD-57A Part 2 and the OLEX, 66.3% of participants experienced at least 10% weight gain, whereas 7.6% of participants experienced at least 5% weight loss. Post-hoc analyses of the age-adjusted changes in body mass index and body weight category shift assessments indicated that most instances of weight gain were associated with children\'s growth (data not shown).

Discussion {#s012}
==========

This is the first report of a prospective, double-blind, randomized, placebo-controlled trial of memantine monotherapy in children with autism. In terms of efficacy, there was no statistically significant between-group difference on the primary efficacy measure, the SRS, at the completion of the randomized, double-blind phase (Week 12). Results from the 12 week and 48 week study periods indicate that both short-term and long-term treatments with memantine ER were well tolerated, with no emergent safety signals.

It may be of some interest that a potentially significant clinical improvement of 10 points on the SRS total raw score (according to the scale\'s author \[Constantino JN, personal communication, 2012\]) was observed after 12 weeks in both treatment groups, and that the SRS scores continued to improve numerically for the duration of the 48 week OLEX phase. This large placebo effect should not be surprising. In children with autism, randomized clinical trials using a variety of treatments have reported placebo response rates of 20--50% (King et al. [@B22]), which could be attributed to several factors, including heightened expectation of parents and caregivers, waxing and waning of symptoms, and positive response to the attention and structure inherent to clinical trials (Sandler [@B33]). In one trial, children who were more symptomatic in composite measures of disruptive behavior, autism/mood, and caregiver strain at baseline were found to be less likely to respond to placebo (King et al. [@B22]), which suggests that the level of baseline symptomatology should be considered in the design and interpretation of future trials in ASD.

Further limitations of the current studies may include the potential lack of sensitivity of the scale used to assess real improvement, the absence of a biological marker that would allow correlation of any clinical improvement with biological changes, and the heterogeneity of ASD symptoms. In addition, numerous outcome measures were used, and some of them had not been validated or tested in previous randomized controlled trials.

We were intrigued by the suggestion of improvement shown by the placebo-treated participants who started receiving memantine ER during OLEX MEM-MD-67 ([Fig. 3](#f3){ref-type="fig"} and [Supplementary Fig. S1](#SD2){ref-type="supplementary-material"}), especially between treatment weeks 18 and 36. Although a post-hoc statistical assessment indicated that this improvement was not statistically significant compared with the memantine-memantine sequence, the observation of a potential signal may inform future strategies for testing the efficacy in regard to core symptoms of ASD. For example, it is possible that up to 18 weeks are needed to eliminate the hope and expectation that accompany participation in a trial such as this one.

The only other randomized trial of memantine in children with ASD was conducted in risperidone-treated children with autism. This trial showed significant benefits of add-on memantine versus add-on placebo on the ABC irritability subscale after 10 weeks of treatment (Ghaleiha et al. [@B17]). However, the study is difficult to compare with ours not only because of the background antipsychotic treatment and different primary efficacy parameter (the ABC), but also because the selection criteria for our trial precluded participation of children with prominent irritability symptoms (see [Methods](#s002){ref-type="sec"}).

Conclusions and Clinical Significance {#s013}
=====================================

In this study, there was no evidence of memantine ER efficacy at the dosages used on core symptoms of autism. The treatment was shown to be safe and well tolerated at the dosages examined: there were no emergent laboratory or ECG concerns, and elevated irritability and agitation (which have been reported in some smaller studies) failed to emerge as significant issues. A good safety profile and a strong placebo effect keep the possibility open that memantine ER could be a viable therapeutic option for *other* conditions affecting children. That, however, remains to be proven in prospective randomized trials.
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======================
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###### Supplemental data

###### Supplemental data
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